European Union: Food, Drugs, Healthcare, Life Sciences

Subscribe
Welcome to the Mondaq Food, Drugs, Healthcare, Life Sciences homepage, here you will find thought leadership articles, podcasts, videos and webinars providing insights covering topics such as Food and Drugs Law, Healthcare, Life Sciences, Biotechnology and Nanotechnology.
Article
A New Era For EU Pharma
The Council of the European Union has formally adopted the EU Pharma Package, marking the most significant revision of EU pharmaceutical legislation since 2004. This comprehensive reform introduces substantial changes to regulatory protection periods, innovation incentives, medicine shortage protocols, and market access mechanisms that will fundamentally reshape how pharmaceutical companies operate across the European Union.
European Union Healthcare
WF
William Fry
Article
A New Regulatory Landscape For Veterinary Manufacturers
Since July 2026, veterinary medicines manufacturers have been subject to restructured good manufacturing practice (GMP) rules under two new EU Regulations. These standalone frameworks introduce mandatory quality obligations for finished products and active substances, replacing previous guidance-based requirements with directly applicable law. Meanwhile, the European Commission's proposed Biotech Act I aims to streamline variation procedures, simplify GMO approvals, and introduce new incentives for biotechn
European Union Healthcare
AC
Arthur Cox
See more

Healthcare

Article
A New Era For EU Pharma
The Council of the European Union has formally adopted the EU Pharma Package, marking the most significant revision of EU pharmaceutical legislation since 2004. This comprehensive reform introduces substantial changes to regulatory protection periods, innovation incentives, medicine shortage protocols, and market access mechanisms that will fundamentally reshape how pharmaceutical companies operate across the European Union.
European Union Healthcare
WF
William Fry
Article
EU Pharmaceutical Package: What The Council’s Revised Texts Mean For Companies
The Council has adopted its position on the EU Pharmaceutical Package at first reading, with legally and linguistically revised texts now available. While the main elements of the political compromise remain intact, several clarifications warrant attention as companies refine their implementation plans. This analysis identifies the most relevant changes in the Council's revised texts, assesses their practical significance, and outlines the next steps in the legislative process.
European Union Healthcare
CK
CMS Kluge Advokatfirma AS
See more

Life Sciences, Biotechnology & Nanotechnology

Article
A New Era For EU Pharma
The Council of the European Union has formally adopted the EU Pharma Package, marking the most significant revision of EU pharmaceutical legislation since 2004. This comprehensive reform introduces substantial changes to regulatory protection periods, innovation incentives, medicine shortage protocols, and market access mechanisms that will fundamentally reshape how pharmaceutical companies operate across the European Union.
European Union Healthcare
WF
William Fry
Article
A New Regulatory Landscape For Veterinary Manufacturers
Since July 2026, veterinary medicines manufacturers have been subject to restructured good manufacturing practice (GMP) rules under two new EU Regulations. These standalone frameworks introduce mandatory quality obligations for finished products and active substances, replacing previous guidance-based requirements with directly applicable law. Meanwhile, the European Commission's proposed Biotech Act I aims to streamline variation procedures, simplify GMO approvals, and introduce new incentives for biotechn
European Union Healthcare
AC
Arthur Cox
See more

Food and Drugs Law

Article
A New Era For EU Pharma
The Council of the European Union has formally adopted the EU Pharma Package, marking the most significant revision of EU pharmaceutical legislation since 2004. This comprehensive reform introduces substantial changes to regulatory protection periods, innovation incentives, medicine shortage protocols, and market access mechanisms that will fundamentally reshape how pharmaceutical companies operate across the European Union.
European Union Healthcare
WF
William Fry
Article
A New Regulatory Landscape For Veterinary Manufacturers
Since July 2026, veterinary medicines manufacturers have been subject to restructured good manufacturing practice (GMP) rules under two new EU Regulations. These standalone frameworks introduce mandatory quality obligations for finished products and active substances, replacing previous guidance-based requirements with directly applicable law. Meanwhile, the European Commission's proposed Biotech Act I aims to streamline variation procedures, simplify GMO approvals, and introduce new incentives for biotechn
European Union Healthcare
AC
Arthur Cox
See more

Latest Videos

See more